Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Published:November 23, 2022DOI:



      This study was conducted to evaluate the clinical feasibility of nab-paclitaxel plus gemcitabine-cisplatin triplet chemotherapy in patients with locally advanced cholangiocarcinoma in real-world practice.


      We retrospectively reviewed patients with locally advanced cholangiocarcinoma who were treated with nab-paclitaxel plus gemcitabine-cisplatin between October 2019 and August 2021 at a single institution. The initial diagnosis of cholangiocarcinoma was histologically confirmed.


      One hundred twenty-nine patients were included in this study. Among the patients with a measurable lesion (57.4%), the objective response rate and disease control were 60.8% and 91.9%, respectively. Seventy-seven patients (59.7%) were determined as resectable after triplet chemotherapy, but 73 (56.6%) underwent subsequent curative surgery. The major postoperative complication rate was 15.1%, and there were 2 postoperative mortalities (2.7%). There were 6 complete remission cases (8.2%) in the final pathology. The R0 resection was achieved in 67 patients (91.8%). Despite the initial locally advanced cholangiocarcinoma, a pathologic T stage of less than T2 was reported in 67 patients (91.8%). Fifty-two patients (71.2%) had no lymph node metastasis. Patients who underwent surgery after triplet chemotherapy had significantly higher 12-month overall survival (95.9% vs 76.8%; P < .001) than those treated with chemotherapy alone.


      Nab-paclitaxel plus gemcitabine-cisplatin chemotherapy demonstrated a down-staging effect through a high response rate, indicating that this triplet chemotherapy is feasible as induction therapy in patients with locally advanced cholangiocarcinoma.

      Graphical abstract

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Valle J.
        • Wasan H.
        • Palmer D.H.
        • et al.
        Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
        N Engl J Med. 2010; 362: 1273-1281
        • Okusaka T.
        • Nakachi K.
        • Fukutomi A.
        • et al.
        Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
        Br J Cancer. 2010; 103: 469-474
        • Jarnagin W.R.
        • Fong Y.
        • DeMatteo R.P.
        • et al.
        Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.
        Ann Surg. 2001; 234 (discussion 517–509): 507-517
        • Jung J.H.
        • Lee H.J.
        • Lee H.S.
        • et al.
        Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma.
        World J Gastroenterol. 2017; 23: 3301-3308
        • Sumiyoshi T.
        • Shima Y.
        • Okabayashi T.
        • et al.
        Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma.
        World J Surgery. 2018; 42: 2910-2918
        • Shroff R.T.
        • Javle M.M.
        • Xiao L.
        • et al.
        Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial.
        Jama Oncol. 2019; 5: 824-830
        • Cheon J.
        • Lee C.K.
        • Sang Y.B.
        • et al.
        Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
        Ther Adv Med Oncol. 2021; 13 (17588359211035983)
        • Sasaki R.
        • Kondo T.
        • Oda T.
        • Murata S.
        • Wakabayashi G.
        • Ohkohchi N.
        Impact of three-dimensional analysis of multidetector row computed tomography cholangioportography in operative planning for hilar cholangiocarcinoma.
        Am J Surg. 2011; 202: 441-448
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Clavien P.A.
        • Barkun J.
        • de Oliveira M.L.
        • et al.
        The Clavien-Dindo classification of surgical complications: five-year experience.
        Ann Surg. 2009; 250: 187-196
        • Rahbari N.N.
        • Garden O.J.
        • Padbury R.
        • et al.
        Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).
        Surgery. 2011; 149: 713-724
        • Bassi C.
        • Marchegiani G.
        • Dervenis C.
        • et al.
        The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after.
        Surgery. 2017; 161: 584-591
        • McMasters K.M.
        • Tuttle T.M.
        • Leach S.D.
        • et al.
        Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma.
        Am J Surg. 1997; 174 (discussion 608–609): 605-608
        • Kato A.
        • Shimizu H.
        • Ohtsuka M.
        • et al.
        Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
        Ann Surg Oncol. 2013; 20: 318-324
        • Ercolani G.
        • Dazzi A.
        • Giovinazzo F.
        • et al.
        Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors?.
        Eur J Surg Oncol. 2015; 41: 1162-1169
        • Murakami Y.
        • Uemura K.
        • Sudo T.
        • et al.
        Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
        Ann Surg Oncol. 2011; 18: 651-658
        • Waseem D.
        • Tushar P.
        Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes.
        Ann Hepatol. 2017; 16: 133-139
        • Zhou Y.
        • Liu S.
        • Wu L.
        • Wan T.
        Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta-analysis of prognostic factors.
        Asian J Surg. 2017; 40: 129-138
        • Yao S.
        • Taura K.
        • Okuda Y.
        • et al.
        Effect of mapping biopsy on surgical management of cholangiocarcinoma.
        J Surg Oncol. 2018; 118: 997-1005
        • Nakanishi Y.
        • Okamura K.
        • Tsuchikawa T.
        • et al.
        Time to recurrence after surgical resection and survival after recurrence among patients with perihilar and distal cholangiocarcinomas.
        Ann Surg Oncol. 2020; 27: 4171-4180
        • Oh D.Y.
        • He A.R.
        • Qin S.
        • et al.
        Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
        NEJM Evid. 2022; 1: 1-11